New Features information at Pharmaceutical Technology New and updated information from Features listed on en-us New Features information at Pharmaceutical Technology PhRMA: resetting the conversation Over the last few years, the issue of drug prices has been rising ever higher on the agenda in the US. Prominent politicians, including former democratic presidential hopeful and champion of American socialism Bernie Sanders, have campaigned hard to … Tue, 25 Jul 2017 23:00:00 GMT Do healthcare cuts risk creating a ‘desert for innovation’ in the UK? The world’s biggest drug companies could reconsider their operations in the UK if the country’s new Government doesn’t increase its spending on NHS treatments and patient access to new medicines, according to the Association of the British Pharmaceut… Sun, 23 Jul 2017 23:00:00 GMT Betting big on Gamma Delta T Cells Gamma Delta T Cells live in our tissue and form a crucial part of our immune system. Until recently, they have been on the sidelines of cancer research, but a $100m cash injection from drug giant Takeda Pharmaceuticals into a small biotech firm with … Thu, 20 Jul 2017 09:27:00 GMT Pharma Technology Focus – Issue 61 In this issue: The UK’s healthcare spending problem, PhRMA’s new R&D spending requirements, undermining supply chain security by importing foreign drugs, milestone cystic fibrosis trials, a personalised treatment approach for panic disorder, and more… Wed, 19 Jul 2017 13:55:00 GMT Cystic fibrosis: searching for a breakthrough There are exciting years ahead for the treatment of cystic fibrosis (CF). This inherited autosomal recessive genetic disorder has proven to be incredibly tough for drug developers, with research efforts hampered by the formidable scientific challenge… Tue, 18 Jul 2017 23:00:00 GMT US drug imports: a recipe for disaster? Many in the US are weighing up whether importing drugs from foreign markets would be a good way to improve patient access to medication. Sun, 16 Jul 2017 23:00:00 GMT Treating mononucleosis: why the mystery? Often abbreviated to 'mono', Mononucleosis is a common viral infection that affects hundreds of thousands of people each year. It is generally caused by the Epstein-Barr virus (EBV), which is one of the most common human viruses in the world. The con… Wed, 12 Jul 2017 23:00:00 GMT Reforming paediatric cancer trials in Europe Cancer experts are calling on European officials to reform outdated rules on clinical trials that allow pharmaceutical companies to opt out of testing new cancer drugs in children even where there is good evidence they could be beneficial. Sun, 09 Jul 2017 23:00:00 GMT Immuno-oncology: where to go in a packed field Over the last decade or so, immuno-oncology has gained a reputation as one of the most exciting areas in medicine. Referring to treatments that harness the immune system in the fight against cancer, it has grown from a niche and somewhat speculative … Wed, 05 Jul 2017 23:00:00 GMT June's top stories: Takeda and Biological E. collaborated, J&J completed Actelion acquisition Takeda and Biological E. collaborated to develop affordable combination vaccines, and J&J completed the Actelion acquisition for $30bn. wraps up the key headlines from June. Tue, 04 Jul 2017 23:00:00 GMT Roundtable: discussing trends in contract manufacturing As outsourced contract manufacturing continues to grow, the need for a trustworthy partner is paramount. Business development director at Idifarma Manuel Leal Sanchez, vice-president of manufacturing services and head of corporate social responsibili… Sun, 02 Jul 2017 23:00:00 GMT Sealed with a kisspeptin: the clinical potential of the ‘love hormone’ Kisspeptin is a hormone produced in the hypothalamus. It holds diverse clinical potential that researchers are only now starting to understand. Sun, 25 Jun 2017 23:00:00 GMT Pharma Technology Focus – Issue 60 In this issue: Solving US drug pricing issues by importing cheaper Canadian drugs, underexplored fields in immuno-oncology, a new temperature-resistant rabies and yellow fever vaccine, the increasingly popularity of adaptive clinical trials, and more… Wed, 21 Jun 2017 13:49:00 GMT Counting the cost of failure in drug development Most people who have a passing association with the pharmaceutical business will be able to give a rough estimate of how much it costs to take a drug candidate through clinical trials and regulatory approval. The estimate would likely be based on som… Mon, 19 Jun 2017 23:00:00 GMT Could a temperature-resistant vaccine spell the end for rabies and yellow fever? Rabies and yellow fever claim tens of thousands of lives every year. Although vaccines do exist, they are either expensive or in short supply. In addition, they need to be transported and stored at controlled temperatures. A consortium led by KU Leuv… Tue, 13 Jun 2017 14:42:00 GMT The gene-silencing approach to cutting cholesterol The Medicine Company’s inclisiran, which is moving into phase III clinical trials, could halve cholesterol in patients at high risk of cardiovascular disease. Unlike all previous treatments, it works by ‘switching off’ one of the genes responsible fo… Tue, 06 Jun 2017 23:00:00 GMT May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken Thermo Fisher Scientific agreed to acquire Dutch contract development and manufacturing organisation (CDMO) Patheon for $7.2bn. AstraZeneca entered an agreement to provide the commercial rights for Seloken / Seloken ZOK and associated Logimax fixed-d… Mon, 05 Jun 2017 23:00:00 GMT Pooling resources for clinical trials Adaptive clinical trial models, which allow researchers to tweak and change a trial as it progresses, are becoming more and more popular. But are pharma companies willing to make the changes to both infrastructure and mind-set to allow for more flexi… Sun, 04 Jun 2017 23:00:00 GMT Are cheap Canadian drugs a solution to US pricing issues? The Affordable and Safe Prescription Drug Importation Act wants to solve the US’s drug pricing issues by bringing in cheaper drugs from Canada. But critics say it’s a band-aid solution that simply isn’t viable. Elly Earls reports. Mon, 29 May 2017 23:00:00 GMT BlueRock: Canada’s stem cell contender on the journey from petri dish to clinical trial Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing. So what stem cell-based therapies is the company working on? Sun, 21 May 2017 23:00:00 GMT